Six-month management of patients following treatment for gastroesophageal reflux disease symptoms - a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting
Summary This study assesses the difference in direct medical costs between on‐demand treatment with esomeprazole 20 mg, continuous treatment with esomeprazole 20 mg once‐daily and continuous treatment with ranitidine 150 mg twice‐daily to prevent symptomatic relapse in patients with gastroesophageal...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical practice (Esher) 2005-06, Vol.59 (6), p.655-664 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 664 |
|---|---|
| container_issue | 6 |
| container_start_page | 655 |
| container_title | International journal of clinical practice (Esher) |
| container_volume | 59 |
| creator | Hansen, A. N. Wahlqvist, P. Jørgensen, E. Bergheim, R. Fagertun, H. Lund, H. Moum, B. |
| description | Summary
This study assesses the difference in direct medical costs between on‐demand treatment with esomeprazole 20 mg, continuous treatment with esomeprazole 20 mg once‐daily and continuous treatment with ranitidine 150 mg twice‐daily to prevent symptomatic relapse in patients with gastroesophageal reflux disease over 26 weeks. Two hundred eighty‐one GP clinics in Norway enrolled 2156 patients to an open, randomized, parallel group, Norwegian society perspective study during 2000–2001. The total direct medical costs of each strategy were 171.9 Euros for on‐demand esomeprazole (n = 634), 221.6 Euros for ranitidine (n = 610) and 248.8 Euros for continuous esomeprazole (n = 658). The total costs for on‐demand and continuous esomeprazole treatment and ranitidine treatment were 221.5, 286.5 and 295.8 Euros, respectively. The highest proportion of costs was because of the study medication cost in each strategy. The on‐demand and continuous treatment strategies with esomeprazole were found to be cost‐effective, compared with ranitidine. |
| doi_str_mv | 10.1111/j.1368-5031.2005.00563.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_67881877</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67881877</sourcerecordid><originalsourceid>FETCH-LOGICAL-i3313-9d3f4df5bc0c0efcd8d32d94c188ee39854d5cca4b0a15758daca30935f8c15a3</originalsourceid><addsrcrecordid>eNpNkl9v0zAUxQMCsTF44QMgv8ATKXYdN87DHlAFY6gaMEA8Wq593XokcbBd2u7Tc_tnjEiRb-LfuffEOUVBGB0xvN7ejBifyFJQzkZjSsUI7wkfbR4Wp6yuxiUbV-wR1nfQSfE0pRtKx0JI-qQ4YaIZV6Lhpw9efPObsgt9XpJO93oBHfSZBEcGnT2WibjQtmHt-wXJEXTe77sQyUKnHAOkMCxRplsSwbWrDbE-gU5A0rYbcugSKYkmVyGuYeF1T6Lubej8Ldg3ZIghDWCy_4N4XtktMaEbdNwPWwI-JTSAAgLOHbgeUtrZw7kdDFHfhhb2BPb12Vvfw38-0aHOOBcS8T3aWKA-otUOrDe4YgPsmn3A14kkyBlHPyseO90meH5cz4ofH95_n34sZ58vLqfvZqXnnPGysdxV1om5oYaCM1ZaPrZNZZiUALyRorLCGF3NqWaiFtJqozltuHDSMKH5WfH60BeP4fcKUladTwbaVvcQVklNaimZrGsEXx7B1RydqyH6TsetuvuLCLw6AjrhZzk8C-PTPTeRk4rzBrnzA7f2LWzv96napUrdqF1g1C4wapcqtU-V2qjLT9MvWKG-POh9yrD5p9fxF5rltVA_ry6U_CqvBbueqYr_BeHK2Qo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67881877</pqid></control><display><type>article</type><title>Six-month management of patients following treatment for gastroesophageal reflux disease symptoms - a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Hansen, A. N. ; Wahlqvist, P. ; Jørgensen, E. ; Bergheim, R. ; Fagertun, H. ; Lund, H. ; Moum, B.</creator><creatorcontrib>Hansen, A. N. ; Wahlqvist, P. ; Jørgensen, E. ; Bergheim, R. ; Fagertun, H. ; Lund, H. ; Moum, B.</creatorcontrib><description>Summary
This study assesses the difference in direct medical costs between on‐demand treatment with esomeprazole 20 mg, continuous treatment with esomeprazole 20 mg once‐daily and continuous treatment with ranitidine 150 mg twice‐daily to prevent symptomatic relapse in patients with gastroesophageal reflux disease over 26 weeks. Two hundred eighty‐one GP clinics in Norway enrolled 2156 patients to an open, randomized, parallel group, Norwegian society perspective study during 2000–2001. The total direct medical costs of each strategy were 171.9 Euros for on‐demand esomeprazole (n = 634), 221.6 Euros for ranitidine (n = 610) and 248.8 Euros for continuous esomeprazole (n = 658). The total costs for on‐demand and continuous esomeprazole treatment and ranitidine treatment were 221.5, 286.5 and 295.8 Euros, respectively. The highest proportion of costs was because of the study medication cost in each strategy. The on‐demand and continuous treatment strategies with esomeprazole were found to be cost‐effective, compared with ranitidine.</description><identifier>ISSN: 1368-5031</identifier><identifier>EISSN: 1742-1241</identifier><identifier>DOI: 10.1111/j.1368-5031.2005.00563.x</identifier><identifier>PMID: 15924593</identifier><language>eng</language><publisher>Oxford, UK; Malden, USA: Blackwell Science Ltd</publisher><subject>Adult ; Anti-Ulcer Agents - administration & dosage ; Anti-Ulcer Agents - economics ; Biological and medical sciences ; Continuous treatment strategy ; Cost-Benefit Analysis ; cost-effectiveness ; Drug Costs ; esomeprazole ; Esomeprazole - administration & dosage ; Esomeprazole - economics ; Esophagus ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Gastroesophageal Reflux - drug therapy ; Gastroesophageal Reflux - economics ; General aspects ; Humans ; Long-Term Care ; Male ; medical costs ; Medical sciences ; Middle Aged ; Norway ; Other diseases. Semiology ; Patient Satisfaction ; Prospective Studies ; Proton Pump Inhibitors ; Ranitidine - administration & dosage ; Ranitidine - economics</subject><ispartof>International journal of clinical practice (Esher), 2005-06, Vol.59 (6), p.655-664</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1368-5031.2005.00563.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1368-5031.2005.00563.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16864339$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15924593$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hansen, A. N.</creatorcontrib><creatorcontrib>Wahlqvist, P.</creatorcontrib><creatorcontrib>Jørgensen, E.</creatorcontrib><creatorcontrib>Bergheim, R.</creatorcontrib><creatorcontrib>Fagertun, H.</creatorcontrib><creatorcontrib>Lund, H.</creatorcontrib><creatorcontrib>Moum, B.</creatorcontrib><title>Six-month management of patients following treatment for gastroesophageal reflux disease symptoms - a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting</title><title>International journal of clinical practice (Esher)</title><addtitle>Int J Clin Pract</addtitle><description>Summary
This study assesses the difference in direct medical costs between on‐demand treatment with esomeprazole 20 mg, continuous treatment with esomeprazole 20 mg once‐daily and continuous treatment with ranitidine 150 mg twice‐daily to prevent symptomatic relapse in patients with gastroesophageal reflux disease over 26 weeks. Two hundred eighty‐one GP clinics in Norway enrolled 2156 patients to an open, randomized, parallel group, Norwegian society perspective study during 2000–2001. The total direct medical costs of each strategy were 171.9 Euros for on‐demand esomeprazole (n = 634), 221.6 Euros for ranitidine (n = 610) and 248.8 Euros for continuous esomeprazole (n = 658). The total costs for on‐demand and continuous esomeprazole treatment and ranitidine treatment were 221.5, 286.5 and 295.8 Euros, respectively. The highest proportion of costs was because of the study medication cost in each strategy. The on‐demand and continuous treatment strategies with esomeprazole were found to be cost‐effective, compared with ranitidine.</description><subject>Adult</subject><subject>Anti-Ulcer Agents - administration & dosage</subject><subject>Anti-Ulcer Agents - economics</subject><subject>Biological and medical sciences</subject><subject>Continuous treatment strategy</subject><subject>Cost-Benefit Analysis</subject><subject>cost-effectiveness</subject><subject>Drug Costs</subject><subject>esomeprazole</subject><subject>Esomeprazole - administration & dosage</subject><subject>Esomeprazole - economics</subject><subject>Esophagus</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Gastroesophageal Reflux - drug therapy</subject><subject>Gastroesophageal Reflux - economics</subject><subject>General aspects</subject><subject>Humans</subject><subject>Long-Term Care</subject><subject>Male</subject><subject>medical costs</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Norway</subject><subject>Other diseases. Semiology</subject><subject>Patient Satisfaction</subject><subject>Prospective Studies</subject><subject>Proton Pump Inhibitors</subject><subject>Ranitidine - administration & dosage</subject><subject>Ranitidine - economics</subject><issn>1368-5031</issn><issn>1742-1241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkl9v0zAUxQMCsTF44QMgv8ATKXYdN87DHlAFY6gaMEA8Wq593XokcbBd2u7Tc_tnjEiRb-LfuffEOUVBGB0xvN7ejBifyFJQzkZjSsUI7wkfbR4Wp6yuxiUbV-wR1nfQSfE0pRtKx0JI-qQ4YaIZV6Lhpw9efPObsgt9XpJO93oBHfSZBEcGnT2WibjQtmHt-wXJEXTe77sQyUKnHAOkMCxRplsSwbWrDbE-gU5A0rYbcugSKYkmVyGuYeF1T6Lubej8Ldg3ZIghDWCy_4N4XtktMaEbdNwPWwI-JTSAAgLOHbgeUtrZw7kdDFHfhhb2BPb12Vvfw38-0aHOOBcS8T3aWKA-otUOrDe4YgPsmn3A14kkyBlHPyseO90meH5cz4ofH95_n34sZ58vLqfvZqXnnPGysdxV1om5oYaCM1ZaPrZNZZiUALyRorLCGF3NqWaiFtJqozltuHDSMKH5WfH60BeP4fcKUladTwbaVvcQVklNaimZrGsEXx7B1RydqyH6TsetuvuLCLw6AjrhZzk8C-PTPTeRk4rzBrnzA7f2LWzv96napUrdqF1g1C4wapcqtU-V2qjLT9MvWKG-POh9yrD5p9fxF5rltVA_ry6U_CqvBbueqYr_BeHK2Qo</recordid><startdate>200506</startdate><enddate>200506</enddate><creator>Hansen, A. N.</creator><creator>Wahlqvist, P.</creator><creator>Jørgensen, E.</creator><creator>Bergheim, R.</creator><creator>Fagertun, H.</creator><creator>Lund, H.</creator><creator>Moum, B.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200506</creationdate><title>Six-month management of patients following treatment for gastroesophageal reflux disease symptoms - a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting</title><author>Hansen, A. N. ; Wahlqvist, P. ; Jørgensen, E. ; Bergheim, R. ; Fagertun, H. ; Lund, H. ; Moum, B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i3313-9d3f4df5bc0c0efcd8d32d94c188ee39854d5cca4b0a15758daca30935f8c15a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Anti-Ulcer Agents - administration & dosage</topic><topic>Anti-Ulcer Agents - economics</topic><topic>Biological and medical sciences</topic><topic>Continuous treatment strategy</topic><topic>Cost-Benefit Analysis</topic><topic>cost-effectiveness</topic><topic>Drug Costs</topic><topic>esomeprazole</topic><topic>Esomeprazole - administration & dosage</topic><topic>Esomeprazole - economics</topic><topic>Esophagus</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Gastroesophageal Reflux - drug therapy</topic><topic>Gastroesophageal Reflux - economics</topic><topic>General aspects</topic><topic>Humans</topic><topic>Long-Term Care</topic><topic>Male</topic><topic>medical costs</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Norway</topic><topic>Other diseases. Semiology</topic><topic>Patient Satisfaction</topic><topic>Prospective Studies</topic><topic>Proton Pump Inhibitors</topic><topic>Ranitidine - administration & dosage</topic><topic>Ranitidine - economics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hansen, A. N.</creatorcontrib><creatorcontrib>Wahlqvist, P.</creatorcontrib><creatorcontrib>Jørgensen, E.</creatorcontrib><creatorcontrib>Bergheim, R.</creatorcontrib><creatorcontrib>Fagertun, H.</creatorcontrib><creatorcontrib>Lund, H.</creatorcontrib><creatorcontrib>Moum, B.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical practice (Esher)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hansen, A. N.</au><au>Wahlqvist, P.</au><au>Jørgensen, E.</au><au>Bergheim, R.</au><au>Fagertun, H.</au><au>Lund, H.</au><au>Moum, B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Six-month management of patients following treatment for gastroesophageal reflux disease symptoms - a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting</atitle><jtitle>International journal of clinical practice (Esher)</jtitle><addtitle>Int J Clin Pract</addtitle><date>2005-06</date><risdate>2005</risdate><volume>59</volume><issue>6</issue><spage>655</spage><epage>664</epage><pages>655-664</pages><issn>1368-5031</issn><eissn>1742-1241</eissn><abstract>Summary
This study assesses the difference in direct medical costs between on‐demand treatment with esomeprazole 20 mg, continuous treatment with esomeprazole 20 mg once‐daily and continuous treatment with ranitidine 150 mg twice‐daily to prevent symptomatic relapse in patients with gastroesophageal reflux disease over 26 weeks. Two hundred eighty‐one GP clinics in Norway enrolled 2156 patients to an open, randomized, parallel group, Norwegian society perspective study during 2000–2001. The total direct medical costs of each strategy were 171.9 Euros for on‐demand esomeprazole (n = 634), 221.6 Euros for ranitidine (n = 610) and 248.8 Euros for continuous esomeprazole (n = 658). The total costs for on‐demand and continuous esomeprazole treatment and ranitidine treatment were 221.5, 286.5 and 295.8 Euros, respectively. The highest proportion of costs was because of the study medication cost in each strategy. The on‐demand and continuous treatment strategies with esomeprazole were found to be cost‐effective, compared with ranitidine.</abstract><cop>Oxford, UK; Malden, USA</cop><pub>Blackwell Science Ltd</pub><pmid>15924593</pmid><doi>10.1111/j.1368-5031.2005.00563.x</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1368-5031 |
| ispartof | International journal of clinical practice (Esher), 2005-06, Vol.59 (6), p.655-664 |
| issn | 1368-5031 1742-1241 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67881877 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Anti-Ulcer Agents - administration & dosage Anti-Ulcer Agents - economics Biological and medical sciences Continuous treatment strategy Cost-Benefit Analysis cost-effectiveness Drug Costs esomeprazole Esomeprazole - administration & dosage Esomeprazole - economics Esophagus Female Gastroenterology. Liver. Pancreas. Abdomen Gastroesophageal Reflux - drug therapy Gastroesophageal Reflux - economics General aspects Humans Long-Term Care Male medical costs Medical sciences Middle Aged Norway Other diseases. Semiology Patient Satisfaction Prospective Studies Proton Pump Inhibitors Ranitidine - administration & dosage Ranitidine - economics |
| title | Six-month management of patients following treatment for gastroesophageal reflux disease symptoms - a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T18%3A53%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Six-month%20management%20of%20patients%20following%20treatment%20for%20gastroesophageal%20reflux%20disease%20symptoms%20-%20a%20Norwegian%20randomized,%20prospective%20study%20comparing%20the%20costs%20and%20effectiveness%20of%20esomeprazole%20and%20ranitidine%20treatment%20strategies%20in%20a%20general%20medical%20practitioners%20setting&rft.jtitle=International%20journal%20of%20clinical%20practice%20(Esher)&rft.au=Hansen,%20A.%20N.&rft.date=2005-06&rft.volume=59&rft.issue=6&rft.spage=655&rft.epage=664&rft.pages=655-664&rft.issn=1368-5031&rft.eissn=1742-1241&rft_id=info:doi/10.1111/j.1368-5031.2005.00563.x&rft_dat=%3Cproquest_pubme%3E67881877%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67881877&rft_id=info:pmid/15924593&rfr_iscdi=true |